Tenaya Therapeutics, Inc.
TNYAAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Mar 12, 2026 | Leerink Partners | Mani Foroohar | $2.00(+111%) | $0.95 | StreetInsider |
| Jan 8, 2026 | Morgan Stanley | $2.00(+150%) | $0.80 | TheFly | |
| Dec 12, 2025 | H.C. Wainwright | $3.00(+241%) | $0.88 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Chardan Capital | maintain | Buy | Mar 12, 2026 |
| Canaccord Genuity | maintain | Buy | Dec 18, 2025 |
| Chardan Capital | maintain | Buy | Dec 12, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 12, 2025 |
| Chardan Capital | maintain | Buy | Nov 10, 2025 |
| HC Wainwright & Co. | maintain | Buy | Sep 2, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 27, 2025 |
| Chardan Capital | maintain | Buy | Aug 7, 2025 |
| Chardan Capital | maintain | Buy | May 9, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 25, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 31, 2025 |
| Canaccord Genuity | maintain | Buy | Mar 13, 2025 |
| Morgan Stanley | maintain | Overweight | Mar 12, 2025 |
| Chardan Capital | maintain | Buy | Mar 12, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 11, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 3, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 14, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 18, 2024 |
| Chardan Capital | maintain | Buy | Dec 18, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 26, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 25, 2024 |
| Chardan Capital | maintain | Buy | Nov 7, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 18, 2024 |
| Canaccord Genuity | maintain | Buy | Oct 18, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jul 8, 2024 |
Earnings History
Next report: Mar 10, 2027 · EPS est. $-0.09| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 4, 2026 | $-0.08 | $-0.10 | $1.7M | $800.0K |
| Aug 5, 2026 | $-0.20 | $-0.07 | $1.1M | $10.0M |
| May 6, 2026 | $-0.09 | $-0.09 | $225.0K | $7.5M |
| Mar 11, 2026 | $-0.12 | $-0.13 | — | $3.0M |
| Nov 10, 2025 | $-0.12 | $-0.15 | — | — |
| Aug 6, 2025 | $-0.14 | $-0.20 | — | — |
| May 7, 2025 | $-0.24 | $-0.18 | — | — |
| Mar 10, 2025 | $-0.28 | $-0.31 | — | — |
News
Tenaya Therapeutics, Inc. (TNYA) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.12 per share a year ago.
Received Regenerative Medicine Advanced Therapy (RMAT) Designation from U.S. FDA for TN-401 Gene Therapy for PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy TN-201 and TN-401 Program Updates on Upcoming Data Readouts and Regulatory Interactions for Pivotal Trial Planning Anticipated by Year-End Current Cash Position Provides Planned Runway into Fourth Quarter 2027 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-s…
Tenaya Therapeutics (NASDAQ: TNYA - Get Free Report) and C4 Therapeutics (NASDAQ: CCCC - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings. Profitability This table compares Tenaya Therapeutics and
Tenaya Therapeutics, Inc. (TNYA) Presents at H.C. Wainwright 28th Annual Global Investment Conference Transcript
RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Company management will host investor meetings at the upcoming H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026 and the Morgan Stanley 24th Annual Global Healthcare…
Tenaya Therapeutics NASDAQ: TNYA expects to provide regulatory and development updates in the fourth quarter for its two cardiac gene therapy programs and its small-molecule candidate TN-301, Chief Financial Officer Eric Hyllengren said during a Canaccord discussion.
Tenaya Therapeutics, Inc. (TNYA) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript